New
Product
Release


BROWSE OUR NEW PRODUCTS

Name Catalog Number
Taq DNA polymerase TQ01-E311
Taq Plus DNA polymerase TQ02-E311
DGKZ, Active D30M-10H
DGKZ, Active D30A-10H
DGKA, Active D21-10FH
EGFR (d746-750 L718Q T790M), Active E10-122E3G
Name Catalog Number
DGKA, Active D21-10FH
EGFR (d746-750 L718Q T790M), Active E10-122E3G
Name Catalog Number
Name Catalog Number
Taq DNA polymerase TQ01-E311
Taq Plus DNA polymerase TQ02-E311
DGKZ, Active D30M-10H
DGKZ, Active D30A-10H
Name Catalog Number
Uridylate Kinase UK05-E311H
SpCas9, Active CS09-E311H
Single-stranded DNA binding protein SS01-C501H
ATP-dependent DNA helicase RecQ, Active AH01-E311H
Name Catalog Number
2019-nCoV Spike protein RBD (IHU) C19SD-G231RH
2019-nCoV Spike protein S1 (IHU) C19S1-G231RH
METTL12 Substrate M332-58
METTL12, Active M332-30G
Methyltransferase Dilution Buffer IV M24-09
Methyltransferase Assay Buffer IV M04-09
DGKE, Active D24-10H
DGKB, Active D22-10H
DGKB (11-E), Active D22-11H
Name Catalog Number
Anti-2019-nCoV Spike (P681H) Mutant (9F7E4) C19S1-6701M
Anti-2019-nCoV Spike (P681H) Mutant C19S1-6701R
PsmCas13b CS13B-E312H
2019-nCoV 3CLpro, Active C19CL-G242H
CK1A1 (E42C), Active C64-12CG
CK1A1 (I35C), Active C64-12BG
DGKA, Active D21-10DH
DGKA, Active D21-10EH
DGKA, Active D21-10CG
DGKD, Active D23-10H

PRODUCT SCOOP

To support the advancement of the next generation of kinase-targeted therapeutic programs, SignalChem has developed over 50 clinically relevant active EGFR mutants, representing the most comprehensive list of this class of proteins in the industry. Epidermal Growth Factor Receptor (EGFR) is an important trans-membrane Receptor Tyrosine Kinase extensively recognized for the role it plays in Cancer. Mutations in the EGFR encoding gene can compromise its biological function resulting in deregulation of key cell-signaling pathways. These alterations are the driving agents in many cancers as non-small cell lung cancer, glioblastoma, and basal-like breast cancer.

Tyrosine kinase inhibitors, targeting critical EGFR mutations have revolutionized targeted therapeutics of multiple key cancers such as non-small cell lung cancer (NSCLC) and has established EGFR's as important drug targets. Furthermore, researchers are constantly being challenged by resistance to EGFR targeting cancer therapies, as a result, altering the clinical implications of these anti-EGFR treatments and drug discovery projects. To tackle these challenges, and aide the global life science community, SignalChem has utilized our protein kinase experts with over 100 years of combined experience in developing an effective line of biologically active recombinant EGFR mutants for the international research community.



Upcoming Events

Come chat with us at the following events:

AACR

New Orleans, USA
April 8-13, 2022

BioEurope Spring

Basel, Switzerland
March 28-30, 2022

ECCMID, 2022

Lisbon, Portugal
April 23-26, 2022

Medlab Asia Pacific

Bangkok, Thailand
Oct 19-21, 2022

Discovery On Target

Boston, USA
Oct 17-20, 2022

Society for Neuroscience

San Diego, USA
Nov 12-16, 2022

Medica

Dusseldorf, Germany
Nov 14-18, 2022

Online Resources

Check out our online resources to help with your research needs.

See All Products

View the comprehensive list of our diverse and high-quality products.

Drug Discovery

Learn more about our kinase focused drug discovery programs.

News Releases

Find the latest news and updates about our company.

Product Related Publications

SIGNALCHEM BIOTECH INC.


About

Terms of Service

Privacy Policy

Get the latest resources, updates and offers in your inbox